GlassScriptPhysician profile
Ammar M Yousif
NPI 1457745531
$22,236.82
in general payments reported to CMS, 2019-2025
79 companies · $5,140 in 2025
The $5,140 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $141 · 2021: $2,138 · 2022: $5,343 · 2023: $4,215 · 2024: $4,626 · 2025: $5,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,946 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,783.76 |
| Long Term Medical Supply Or Device Loan | $1,946.37 |
| Education | $250.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,324.48 | 2022-2025 | |
| Incyte Corporation | $1,239.01 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $1,196.01 | 2021-2025 | Darzalex, Rybrevant, Talvey |
| Merck Sharp & Dohme LLC | $895.97 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $865.84 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $846.91 | 2021-2025 | Xtandi, Xospata, Vyloy |
| Celgene Corporation | $813.39 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $729.03 | 2020-2023 | Vectibix, Nplate, Lumakras |
| Astrazeneca Pharmaceuticals LP | $681.74 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $615.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $576.04 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Sobi, INC | $541.72 | 2022-2025 | |
| Eisai INC. | $541.36 | 2022-2025 | |
| Beigene USA, INC. | $487.85 | 2021-2025 | Brukinsa |
| Exelixis INC. | $487.52 | 2021-2025 | Cabometyx |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $471.72 | 2021-2024 | Zejula, Ojjaara |
| Emd Serono, INC. | $471.59 | 2021-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $430.63 | 2021-2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $360.50 | 2019-2025 | Fruzaqla, Vpriv, Alunbrig |
| Seagen INC. | $338.62 | 2019-2023 | Padcev |
| Genentech USA, INC. | $318.92 | 2021-2025 | Tecentriq, Perjeta, Polivy |
| Gilead Sciences, INC. | $315.73 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $307.68 | 2020-2025 | Libtayo |
| Genzyme Corporation | $262.56 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.62 | 2021-2025 | Gilotrif |
| Lilly USA, LLC | $226.73 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Sanofi-Aventis U.S. LLC | $222.97 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $217.84 | 2023-2024 | Cellsearch |
| Genmab U.S., INC. | $206.87 | 2022-2025 | Epkinly, Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $193.05 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $190.54 | 2020-2024 | |
| Stemline Therapeutics INC. | $181.70 | 2019-2025 | Orserdu, Elzonris |
| Puma Biotechnology, INC. | $168.88 | 2022-2025 | |
| Myovant Sciences INC. | $166.79 | 2021-2022 | |
| Sirtex Medical INC | $157.89 | 2022-2025 | Sir-Spheres Microspheres |
| Kite Pharma, INC. | $146.05 | 2019-2024 | Yescarta |
| Abbvie INC. | $145.38 | 2020-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $144.38 | 2019-2022 | |
| Array Biopharma INC | $143.50 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Ipsen Biopharmaceuticals, INC | $142.78 | 2019-2025 | Onivyde, Tazverik |
| Pharmacosmos Therapeutics INC. | $122.59 | 2022-2024 | Monoferric |
| Foundation Medicine, INC. | $119.66 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $117.79 | 2022-2025 | Provenge |
| Recordati_rare_diseases_inc. | $107.16 | 2024-2025 | Sylvant, Enjaymo |
| Karyopharm Therapeutics INC. | $98.13 | 2022-2025 | Xpovio |
| Beone Medicines USA, INC. | $96.22 | 2025 | Brukinsa, Tevimbra |
| Clovis Oncology, INC. | $95.72 | 2021-2022 | |
| Taiho Oncology, INC. | $89.30 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $89.12 | 2023-2024 | Orgovyx |
| Mirati Therapeutics, INC. | $87.71 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $78.34 | 2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $78.18 | 2022-2024 | Qinlock |
| Eusa Pharma (US) LLC | $72.11 | 2021-2022 | |
| Coherus Oncology, INC. | $71.32 | 2023-2025 | Loqtorzi |
| Springworks Therapeutics, INC. | $69.99 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $66.98 | 2022-2023 | Vonjo |
| Servier Pharmaceuticals LLC | $66.64 | 2022-2023 | |
| Geron Corporation | $61.91 | 2025 | Rytelo |
| Tempus Ai, INC | $58.67 | 2024-2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $53.89 | 2023-2025 | Besremi |
| Organon LLC | $47.90 | 2021-2023 | Ontruzant |
| Kyowa Kirin, INC. | $41.93 | 2025 | |
| G1 Therapeutics, INC. | $39.74 | 2022-2023 | Cosela |
| Ge Healthcare | $38.75 | 2022 | |
| Blueprint Medicines Corporation | $38.15 | 2021-2022 | |
| Tersera Therapeutics LLC | $33.96 | 2023 | Xermelo |
| Sun Pharmaceutical Industries INC. | $33.83 | 2024 | |
| Fresenius Kabi USA, LLC | $33.12 | 2023 | Stimufend |
| Alnylam Pharmaceuticals INC. | $25.75 | 2023 | Givlaari |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Macrogenics, INC. | $21.99 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.86 | 2024 | Empaveli |
| Novocure INC. | $21.67 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.59 | 2025 | Pyrukynd |
| Dova Pharmaceuticals | $18.77 | 2021 | |
| Aveo Pharmaceuticals, INC. | $18.66 | 2023 | Fotivda |
| Aadi Bioscience, INC. | $17.44 | 2024 | Fyarro |
| Acrotech Biopharma INC. | $14.36 | 2022 | |
| Tactile Systems Technology INC | $13.94 | 2022 |
Drugs and devices associated with these payments
Kisqali $1,962Keytruda $666Enhertu $583Doptelet $492Cabometyx $367Imfinzi $330Lenvima $321Brukinsa $320Reblozyl $313Opdivo $310Jakafi $288Zejula $263Xtandi $249Ultomiris $220Scemblix $219Cellsearch $218Rybrevant $217Imbruvica $213Darzalex $211Trodelvy $201Orgovyx $182Pluvicto $181Padcev $179Talvey $177Libtayo $173Fabhalta $171Bavencio $168Epkinly $166Sir-Spheres Microspheres $146Ojjaara $142Datroway $138Welireg $134Tecvayli $134Gilotrif $127Orserdu $126Talzenna $116Lynparza $115Zepzelca $112Tecentriq $111Vectibix $102Carvykti $98.49Monjuvi $94.53Provenge $94.19Erleada $90.12Krazati $87.71Calquence $85.91Xpovio $83.50Tivdak $80.35Bosulif $78.44Sylvant $78.31Opdualag $77.58Nplate $76.19Inlyta $75.64Venclexta $74.73Lorbrena $70.76Ogsiveo $69.99Oxbryta $68.59Nerlynx $65.42Qinlock $64.44Lutathera $63.48Elrexfio $61.99Rytelo $61.91Pomalyst $61.09Jaypirca $60.82Verzenio $60.82Xospata $58.60Fruzaqla $57.26Polivy $56.29Phesgo $56.29Perjeta $56.29Loqtorzi $56.02Keytruda Qlex $55.50Besremi $53.89Braftovi $53.77Onivyde $53.45Vpriv $53.01Lumakras $52.49Enjaymo $51.70Paxlovid $48.38Eliquis $48.38Tibsovo $47.76Oncaspar $47.76Vonjo $46.94Alunbrig $45.41Stivarga $45.18Mektovi $44.63Monoferric $43.70Xofigo $43.47Nubeqa $43.47Zynyz $42.20Poteligeo $41.93Vyloy $40.37Promacta $37.34Ibrance $34.76Tukysa $34.76Injectafer $34.30Xermelo $33.96Tazverik $33.88Odomzo $33.83Yonsa $33.83
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Yousif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.